EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS: Case 4

Video

EGFR Testing for Metastatic Non-Small Cell Lung Cancer with Jonathan W. Riess, MD, MS

Riess case 4:

52-year-old man with relapsed metastatic NSCLC.

  • 52-year-old man developed NSCLC, metastatic to the bone and brain
  • Was found to have an EGFR activating mutation
  • Started on erlotinib with a good response, received radiotherapy to hip and brain
  • After 12 months he developed cough and dyspnea on exertion
  • CT scan showed progression in the primary lesion and multiple other pulmonary nodules
  • Tissue biopsy showed an EGFR T790M mutation
  • Subsequent treatment with osimertinib resulted in tumor shrinkage as well as resolution of his symptoms.
Related Videos
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content